Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      NuVasive Announces First Quarter 2019 Financial Results

      NuVasive Logo

      News provided by

      NuVasive, Inc.

      May 01, 2019, 16:02 ET

      Share this article

      Share this article


      SAN DIEGO, May 1, 2019 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2019.

      First Quarter 2019 Highlights

      • Revenue increased 5.5% to $274.8 million, or 6.4% on a constant currency basis;
      • GAAP operating profit margin of 7.3%; Non-GAAP operating profit margin of 14.9%; and
      • GAAP diluted earnings per share of $0.18; Non-GAAP diluted earnings per share of $0.53.

      "In the first quarter 2019, NuVasive delivered a solid start to the year with focused execution across our U.S. Spinal Hardware, U.S. Surgical Support and International businesses," said Chris Barry, chief executive officer of NuVasive. "Coupled with these financial results, we continued to operate the business with rigor and discipline to drive profitability while strategically investing in key growth areas. This includes the recently launched X360 System for lateral single-position surgery integrated with Surgical Intelligence, further differentiation of our Advanced Materials Science portfolio and upcoming launch of the Pulse platform—all which enable our surgeon partners to provide better, more reproducible clinical outcomes for their patients through minimally invasive surgery."

      A full reconciliation of GAAP to non-GAAP financial measures can be found in the tables of this news release.

      First Quarter 2019 Results
      NuVasive reported first quarter 2019 total revenue of $274.8 million, a 5.5% increase compared to $260.5 million for the first quarter 2018. On a constant currency basis, first quarter 2019 total revenue increased 6.4% compared to the same period last year.

      For the first quarter 2019, both GAAP and non-GAAP gross profit was $200.3 million and GAAP and non-GAAP gross margin was 72.9%. These results compared to GAAP and non-GAAP gross profit of $186.7 million and $187.1 million, respectively, and GAAP and non-GAAP gross margin of 71.7% and 71.8%, respectively, for the first quarter 2018.

      The Company reported GAAP net income of $9.4 million, or diluted earnings per share of $0.18, for the first quarter 2019 compared to a GAAP net loss of $(27.1) million, or diluted loss per share of $(0.53), for the first quarter 2018. On a non-GAAP basis, the Company reported net income of $27.6 million, or diluted earnings per share of $0.53 per share, for the first quarter 2019 compared to net income of $20.6 million, or diluted earnings per share of $0.40 per share, for the first quarter 2018.

      Annual Financial Guidance for 2019
      The Company reiterated its full-year 2019 guidance:


      2019 Guidance Range 1


      Prior


      Current


       GAAP 

       Non-GAAP 


       GAAP 

       Non-GAAP 

      Revenue

       $1.14B - $1.16B 


       $1.14B - $1.16B 


       $1.14B - $1.16B 


       $1.14B - $1.16B 

        % Growth - Reported

      3.5% - 5.5%


      3.5% - 5.5%


      3.5% - 5.5%


      3.5% - 5.5%

      % Growth - Constant Currency2



      3.8% - 5.8%




      3.8% - 5.8%

      Operating margin

      9.5% - 10.0%


      15.0% - 15.5%


      9.0% - 9.5%


      15.0% - 15.5%

      Earnings per share

       $1.00 - $1.10 


       $2.20 - $2.30 


       $0.95 - $1.05 


       $2.20 - $2.30 

      EBITDA margin

      21.2% - 21.7%


      25.2% - 25.7%


      20.9% - 21.3%


      25.2% - 25.7%

      Tax Rate

      ~24%


      ~23%


      ~22%


      ~23%


           1

      Prior guidance reflects the range provided February 20, 2019. Current guidance reflects the range provided May 1, 2019.

           2

      Constant currency is a measure that adjusts US GAAP revenue for the impact of currency over the same period in the prior year.

      • The Company estimates revenue for full year 2019 to be in the range of $1.14 billion to $1.16 billion, reflecting reported growth in the range of 3.5% to 5.5%;
      • Non-GAAP earnings per share in a range of $2.20 to $2.30;
      • Non-GAAP operating profit margin of 15.0% to 15.5%;
      • EBITDA margin of 25.2% to 25.7%; and
      • Non-GAAP effective tax expense rate of approximately 23%.

      Supplementary Financial Information
      For additional financial detail, please visit the Investor Relations section of the Company's website at www.nuvasive.com to access Supplementary Financial Information.

      Reconciliation of Full Year EPS Guidance




      2019 Guidance Range  1, 2


      2018

      Actuals 1


      Prior 3


      Current 4

      GAAP net income per share

      $0.24


       $1.00 - 1.10 


       $0.95 - 1.05 

      Impact of change to diluted share count

      —


      —


      —

      GAAP net income per share, adjusted to diluted Non-GAAP share count

      $0.24


       $1.00 - 1.10 


       $0.95 - 1.05 







      Business transition costs 5

      0.22


      —


      0.10

      Non-cash purchase accounting adjustments on acquisitions 6

      0.02


      —


      —

      Non-cash interest expense on convertible notes

      0.32


      0.30


      0.30

      Litigation related expenses and settlements 7

      0.65


      0.20


      0.20

      Non-recurring consulting fees 8

      0.12


      —


      —

      Net loss on strategic investments

      0.07


      —


      —

      Amortization of intangible assets

      0.97


      0.90


      0.95

      Purchase of in-process research and development 9

      0.17


      —


      —

      European medical device regulation10

      0.01


      0.10


      0.10

      Tax effect of adjustments11

      (0.56)


      (0.30)


      (0.40)

      Non-GAAP earnings per share

      $2.23


       $2.20 - 2.30 


       $2.20 - 2.30 







      GAAP Weighted shares outstanding - basic

      51,382


      52,017


      51,999

      GAAP Weighted shares outstanding - diluted

      52,355


      52,938


      52,991

      Non-GAAP Weighted shares outstanding - diluted 12

      52,178


      52,714


      52,718




      1

      Items may not foot due to rounding.

      2

      Prior guidance reflects the range provided February 20, 2019. Current guidance reflects the range provided May 1, 2019.

      3

      Effective tax expense rate of ~24% applied to GAAP earnings and ~23% applied to Non-GAAP earnings.

      4

      Effective tax expense rate of ~22% applied to GAAP earnings and ~23% applied to Non-GAAP earnings.

      5

      Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

      6

      Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold.

      7

      Represents the loss recorded in connection with the settlement of the Madsen Medical, Inc. litigation matter, as well as expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property.

      8

      Non-recurring consulting fees associated with the implementation of our state tax-planning strategy.

      9

      Purchase of an in-process research and development asset which had no future alternative use.

      10

      Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.

      11

      The impact on results from taxes include tax effecting the adjustments above at the statutory rate as well as taking into account discrete items and including those discrete items in the annual effective tax rate calculation. The Company also includes those adjustments that would have benefited the tax rate in lieu of the above adjustments as part of the Company's tax filings. The impact of the changes to the tax rate results in an annual rate of ~43% benefit on a GAAP basis and ~18% on a non-GAAP basis in 2018.

      12

      Adjusted non-GAAP diluted WASO excludes the impact of dilutive convertible notes and warrants for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

      Reconciliation of Non-GAAP Operating Margin %












      2019 Guidance Range 1, 2

      (in thousands, except %)


      2018
      Actuals 1


      Prior


      Current

      Non-GAAP Gross Margin % [A]


      71.9%


      72.5% - 73.0%


      72.5% - 73.0%

      Non-cash purchase accounting adjustments on acquisitions 3


      (0.1%)


      0.0%


      0.0%

      GAAP Gross Margin [B]


      71.8%


      72.5% - 73.0%


      72.5% - 73.0%








      Non-GAAP Sales, Marketing & Administrative Expense [C]


      51.1%


      51.0% - 52.0%


      51.0% - 52.0%

      Non-recurring consulting fees4


      0.6%


      0.0%


      0.0%

      Litigation related expenses5


      0.6%


      0.7%


      0.7%

      GAAP Sales, Marketing & Administrative Expense [D]


      52.3%


      51.7% - 52.7%


      51.7% - 52.7%








      GAAP and Non-GAAP Research & Development Expense [E]


      5.6%


      6.0%


      6.0%








      Litigation related settlements [F]6


      2.5%


      0.0%


      0.0%

      Amortization of intangible assets [G]


      4.6%


      4.2%


      4.3%

      Purchase of in-process research and development [H]7


      0.8%


      0.0%


      0.0%

      European medical device regulation [I]8


      0.0%


      0.6%


      0.6%

      Business transition costs [J] 9


      1.0%


      0.0%


      0.4%








      Non-GAAP Operating Margin % [A - C - E]


      15.1%


      15.0% - 15.5%


      15.0% - 15.5%








      GAAP Operating Margin % [B - D - E - F - G - H - I - J]


      4.9%


      9.5% - 10.0%


      9.0% - 9.5%



      1

      Items may not foot due to rounding.

      2

      Prior guidance reflects the range provided February 20, 2019. Current guidance reflects the range provided May 1, 2019.

      3

      Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold.

      4

      Non-recurring consulting fees associated with the implementation of our state tax-planning strategy.

      5

      Expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property.

      6

      Represents the loss recorded in connection with the settlement of the Madsen Medical, Inc. litigation matter.

      7

      Purchase of an in-process research and development asset which had no future alternative use.

      8

       

      Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.

      9

      Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

      Reconciliation of EBITDA Margin %










      2019 Guidance Range1, 5

      (in thousands, except %)

      2018 Actuals 1, 2


      Prior 3


      Current4

      Net Income

      1.1%


      4.6% - 5.0%


      4.3% - 4.8%

      Interest income / expense, net 

      3.4%


      3.3%


      3.3%

      Income tax benefit / (expense)

      (0.3%)


      1.5%


      1.3%

      Depreciation and amortization

      11.8%


      11.7%


      12.0%

      EBITDA Margin

      16.0%


      21.2% - 21.7%


      20.9% - 21.3%

      Non-cash stock based compensation

      2.3%


      2.7%


      2.6%

      Business transition costs6

      1.0%


      0.0%


      0.4%

      Non-cash purchase accounting adjustments on acquisitions7

      0.1%


      0.0%


      0.0%

      Litigation related expenses and settlements 8

      3.1%


      0.7%


      0.7%

      Non-recurring consulting fees 9

      0.6%


      0.0%


      0.0%

      In-process research and development10

      0.8%


      0.0%


      0.0%

      European medical device regulation11

      0.0%


      0.6%


      0.6%

      Net loss on strategic investments

      0.3%


      0.0%


      0.0%

      Adjusted EBITDA Margin

      24.3%


      25.2% - 25.7%


      25.2% - 25.7%



      1

      Items may not foot due to rounding.

        2

      Effective tax expense rate of ~43% benefit applied to GAAP earnings and ~18% applied to Non-GAAP earnings.

       3

      Effective tax expense rate of ~24% applied to GAAP earnings and ~23% applied to Non-GAAP earnings.

      4

      Effective tax expense rate of ~22% applied to GAAP earnings and ~23% applied to Non-GAAP earnings.

      5

      Prior guidance reflects the range provided February 20, 2019. Current guidance reflects the range provided May 1, 2019.

      6

      Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

      7

      Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold.

      8

      Represents the loss recorded in connection with the settlement of the Madsen Medical, Inc. litigation matter, as well as expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property.

      9

      Non-recurring consulting fees associated with the implementation of our state tax-planning strategy.

      10

      Purchase of an in-process research and development asset which had no future alternative use.

      11

      Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.

      Reconciliation of Non-GAAP Information
      Management uses certain non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating profit margin, which exclude amortization of intangible assets, business transition costs, purchased in-process research and development, one-time restructuring and related items in connection with acquisitions, investments and divestitures, non-recurring consulting fees, certain litigation expenses and settlements, certain European medical device regulation costs, gains and losses from strategic investments, and non-cash interest expense (excluding debt issuance cost). Management also uses certain non-GAAP measures which are intended to exclude the impact of foreign exchange currency fluctuations. The measure constant currency utilizes an exchange rate that eliminates fluctuations when calculating financial performance numbers. The Company also uses measures such as free cash flow, which represents cash flow from operations less cash used in the acquisition and disposition of capital. Additionally, the Company uses an adjusted EBITDA measure which represents earnings before interest, taxes, depreciation and amortization and excludes the impact of stock-based compensation, business transition costs, purchased in-process research and development, one-time restructuring and related items in connection with acquisitions, investments and divestitures, non-recurring consulting fees, certain litigation expenses and settlements, certain European medical device regulation costs, gains and losses on strategic investments, and other significant one-time items.

      Management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to further and more consistently analyze the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional information to enable them to assess, in the same way management assesses, the Company's current and future continuing operations. These non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from non-GAAP measures used by other companies. Set forth below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measure.

      During the quarter ended June 30, 2018, the Company began excluding from its non-GAAP financial results certain litigation related expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property. For consistency and comparability, the Company has re-casted non-GAAP financial results for each of the quarters ended Dec. 31, 2017 and March 31, 2018 to exclude these litigation expenses in such periods, which were $0.4 million and $0.6 million, respectively.

      For the Three Months Ended March 31, 2019

      Reconciliation of GAAP to Non-GAAP Financial Measures

      (Unaudited - in thousands, except per share data)









      Gross
      Profit

      Operating
      Profit

      Net
      Income 

      Diluted
      EPS

      Diluted
      WASO 5

      Net Income
      to Adjusted
      EBITDA

      Reported GAAP

      $      200,282

      $         20,173

      $         9,386

      $   0.18

      52,480

      $                       9,386

      % of revenue

      72.9%

      7.3%





      Amortization of intangible assets


      13,625

      13,625




      Litigation related expenses and settlements1


      3,046

      3,046



      3,046

      Business transition costs2


      3,833

      3,833



      3,833

      European medical device regulation3


      332

      332



      332

      Non-cash interest expense on convertible notes



      4,319




      Tax effect of adjustments 4



      (6,933)




      Interest expense/(income), net






      9,104

      Income tax expense






      1,317

      Depreciation and amortization






      34,054

      Non-cash stock based compensation






      5,717

      Adjusted Non-GAAP

      $      200,282

      $         41,009

      $       27,608

      $   0.53

      52,480

      $                     66,789

      % of revenue

      72.9%

      14.9%




      24.3%



      1

      Represents expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property.

      2

      Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

      3

      Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.

      4

      Represents the impact from tax affecting the adjustments above at their statutory tax rate. As of May 1, 2019, the Company estimated an annual tax rate of ~22% on a GAAP basis and ~23% on a non-GAAP basis.

      5

      Adjusted non-GAAP diluted WASO excludes the impact of dilutive convertible notes and warrants for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

      For the Three Months Ended March 31, 2018

      Reconciliation of GAAP to Non-GAAP Financial Measures

      (Unaudited - in thousands, except per share data)









      Gross
      Profit

      Operating
      Profit
      (Loss)

      Net Income
      (Loss)

      Diluted
      EPS

      Diluted
      WASO 6

      Net Income
      (Loss) to
      Adjusted
      EBITDA

      Reported GAAP

      $      186,708

      $       (18,222)

      $      (27,132)

      $ (0.53)

      51,226

      $                   (27,132)

      % of revenue

      71.7%

      (7.0%)





      Non-cash purchase accounting adjustments on acquisitions 1

      405

      405

      405



      405

      Non-recurring consulting fees 2


      6,084

      6,084



      6,084

      Amortization of intangible assets


      12,425

      12,425




      Litigation related expenses and settlements 3


      29,586

      29,586



      29,586

      Business transition costs 4


      2,253

      2,253



      2,253

      Non-cash interest expense on convertible notes



      4,099




      Net loss on strategic investments



      9,004



      9,004

      Tax effect of adjustments 5



      (16,109)




      Interest expense/(income), net






      9,333

      Income tax benefit






      (10,126)

      Depreciation and amortization






      32,090

      Non-cash stock based compensation






      4,134

      Adjusted Non-GAAP

      $      187,113

      $         32,531

      $       20,615

      $   0.40

      51,742

      $                     55,631

      % of revenue

      71.8%

      12.5%




      21.4%



      1

      Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold.

      2

      Non-recurring consulting fees associated with the implementation of our state tax-planning strategy.

      3

      Represents the loss recorded in connection with the settlement of the Madsen Medical, Inc. litigation matter, as well as expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property.

      4

      Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

      5

      Represents the impact from tax affecting the adjustments above at their statutory tax rate. As of May 1, 2018, the Company estimated an annual tax rate of ~31% on a GAAP basis and ~23% on a non-GAAP basis.

      6

      Adjusted non-GAAP diluted WASO excludes the impact of dilutive convertible notes and warrants for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

      Investor Conference Call
      NuVasive will hold a conference call today at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the first quarter 2019. The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers. A live webcast of the conference call will be available online from the Investor Relations page of the Company's website at www.nuvasive.com. After the live webcast, the call will remain available on NuVasive's website through May 31, 2019. In addition, a telephone replay of the call will be available until May 8, 2019. The replay dial-in numbers are 1-844-512-2921 for domestic callers and 1-412-317-6671 for international callers. Please use pin number: 13689332.

      About NuVasive
      NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company's portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With more than $1 billion in revenues, NuVasive has approximately 2,600 employees and operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

      Forward-Looking Statements
      NuVasive cautions you that statements included in this news release or made on the investor conference call referenced herein that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward looking statements. In addition, this news release contains selected financial results from the first quarter 2019, as well as projections for 2019 financial guidance and longer-term financial performance goals. The Company's results for the first quarter 2019 are prior to the completion of review and audit procedures by the Company's external auditors and are subject to adjustment. In addition, the Company's projections for 2019 financial guidance and longer-term financial performance goals represent initial estimates, and are subject to the risk of being inaccurate because of the preliminary nature of the forecasts, the risk of further adjustment, or unanticipated difficulty in selling products or generating expected profitability. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products (including the iGA® platform), the Company's ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties more fully described in the Company's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

      NuVasive, Inc. 

      Consolidated Statements of Operations 

      (in thousands, except per share data)








      Three Months Ended March 31,

      (unaudited)


      2019


      2018

      Revenue





      Product revenue


      $ 243,823


      $ 233,515

      Service revenue


      30,953


      27,007

      Total revenue


      274,776


      260,522

      Cost of revenue (excluding below amortization of intangible assets)





      Cost of products sold 


      54,486


      55,191

      Cost of services


      20,008


      18,623

      Total cost of revenue


      74,494


      73,814

      Gross profit


      200,282


      186,708

      Operating expenses:





      Sales, marketing and administrative


      145,076


      146,766

      Research and development


      17,575


      14,491

      Amortization of intangible assets


      13,625


      12,425

      Litigation liability loss


      —


      28,995

      Business transition costs


      3,833


      2,253

      Total operating expenses


      180,109


      204,930

      Interest and other expense, net:





      Interest income


      409


      134

      Interest expense


      (9,513)


      (9,467)

      Other (expense) income, net


      (366)


      (9,703)

      Total interest and other expense, net


      (9,470)


      (19,036)

      Income (loss) before income taxes


      10,703


      (37,258)

      Income tax (expense) benefit


      (1,317)


      10,126

      Consolidated net income (loss)


      $     9,386


      $ (27,132)






      Net income (loss) per share:





      Basic


      $       0.18


      $     (0.53)

      Diluted


      $       0.18


      $     (0.53)

      Weighted average shares outstanding:





      Basic


      51,675


      51,226

      Diluted


      52,480


      51,226

      NuVasive, Inc. 

      Consolidated Balance Sheets 

      (in thousands, except par values and share amounts) 








      March 31, 2019


      December 31, 2018

      ASSETS


      (unaudited)



      Current assets:





      Cash and cash equivalents


      $            93,391


      $                117,840

      Accounts receivable, net of allowances of $16,125 and $16,171, respectively


      194,358


      196,487

      Inventory, net


      288,539


      273,244

      Prepaid income taxes


      16,484


      16,905

      Prepaid expenses and other current assets


      13,555


      13,733

      Total current assets


      606,327


      618,209

      Property and equipment, net


      247,533


      238,841

      Intangible assets, net


      240,663


      252,048

      Goodwill


      561,235


      561,366

      Operating lease right-of-use assets


      61,400


      —

      Deferred tax assets


      4,369


      5,263

      Restricted cash and investments


      2,395


      2,395

      Other assets


      27,180


      29,737

      Total assets


      $       1,751,102


      $             1,707,859

      LIABILITIES AND EQUITY





      Current liabilities:





      Accounts payable and accrued liabilities


      $            99,991


      $                105,877

      Contingent consideration liabilities


      6,637


      7,560

      Accrued payroll and related expenses


      44,824


      59,960

      Operating lease liabilities


      6,320


      —

      Litigation liabilities


      2,045


      1,415

      Income tax liabilities


      1,964


      4,648

      Total current liabilities


      161,781


      179,460

      Senior convertible notes


      607,607


      602,526

      Deferred and income tax liabilities


      5,641


      4,964

      Operating lease liabilities


      67,112


      —

      Other long-term liabilities


      68,955


      86,384

      Commitments and contingencies





      Stockholders' equity:





      Preferred stock, $0.001 par value; 5,000,000 shares authorized, none outstanding


      —


      —

      Common stock, $0.001 par value; 120,000,000 shares authorized at March 31, 2019 and December 31, 2018, 57,119,047 and 56,648,077 issued and outstanding at March 31, 2019 and December 31, 2018, respectively


      61


      61

      Additional paid-in capital


      1,402,797


      1,397,829

      Accumulated other comprehensive loss


      (9,122)


      (8,628)

      Retained earnings


      26,627


      17,241

      Treasury stock at cost; 5,262,478 shares and 5,116,496 shares at March 31, 2019 and December 31, 2018, respectively


      (580,357)


      (571,978)

      Total equity


      840,006


      834,525

      Total liabilities and equity


      $       1,751,102


      $             1,707,859

      NuVasive, Inc. 

      Consolidated Statements of Cash Flows 

      (in thousands) 








      Three Months Ended March 31,

      (unaudited)


      2019


      2018

      Operating activities:





      Consolidated net income (loss)


      $   9,386


      $ (27,132)

      Adjustments to reconcile net income (loss) to net cash provided by operating activities:





      Depreciation and amortization


      34,054


      32,090

      Impairment of strategic investment


      —


      9,003

      Amortization of non-cash interest


      5,210


      4,925

      Stock-based compensation


      5,717


      4,134

      Reserves on current assets


      3,785


      4,080

      Other non-cash adjustments


      2,816


      4,456

      Deferred income taxes


      1,547


      (12,671)

      Changes in operating assets and liabilities, net of effects from acquisitions:





      Accounts receivable


      1,620


      16,933

      Inventory


      (19,292)


      (12,126)

      Prepaid expenses and other current assets


      (1,399)


      (1,737)

      Accounts payable and accrued liabilities


      (2,523)


      1,579

      Accrued payroll and related expenses


      (14,815)


      (18,493)

      Litigation liability


      630


      30,040

      Income taxes


      (2,261)


      1,294

      Net cash provided by operating activities


      24,475


      36,375

      Investing activities:





      Acquisitions and investments


      —


      (51,794)

      Purchases of intangible assets


      (6,827)


      (2,657)

      Purchases of property and equipment


      (33,929)


      (29,109)

      Net cash used in investing activities


      (40,756)


      (83,560)

      Financing activities:





      Proceeds from the issuance of common stock


      —


      336

      Purchases of treasury stock


      (8,177)


      (2,155)

      Payment of contingent consideration


      (1,435)


      (8,900)

      Proceeds from revolving line of credit


      —


      65,000

      Repayments on revolving line of credit


      —


      (10,000)

      Other financing activities


      1,556


      (141)

      Net cash (used in) provided by financing activities


      (8,056)


      44,140

      Effect of exchange rate changes on cash


      (112)


      982

      Decrease in cash, cash equivalents and restricted cash


      (24,449)


      (2,063)

      Cash, cash equivalents and restricted cash at beginning of period


      120,235


      78,198

      Cash, cash equivalents and restricted cash at end of period


      $ 95,786


      $  76,135

      SOURCE NuVasive, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.